- Home
- ARTL vs NDRA Comparison
ARTL vs NDRA Comparison
Compare ARTL & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTL
- NDRA
- Stock Information
- Founded
- ARTL 2011
- NDRA 2007
- Country
- ARTL United States
- NDRA United States
- Employees
- ARTL N/A
- NDRA N/A
- Industry
- ARTL Biotechnology: Pharmaceutical Preparations
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ARTL Health Care
- NDRA Health Care
- Exchange
- ARTL Nasdaq
- NDRA Nasdaq
- Market Cap
- ARTL 3.7M
- NDRA 3.6M
- IPO Year
- ARTL N/A
- NDRA 2017
- Fundamental
- Price
- ARTL $1.21
- NDRA $6.01
- Analyst Decision
- ARTL Strong Buy
- NDRA Strong Buy
- Analyst Count
- ARTL 2
- NDRA 1
- Target Price
- ARTL $5.50
- NDRA $14,000.00
- AVG Volume (30 Days)
- ARTL 28.9K
- NDRA 36.2K
- Earning Date
- ARTL 11-12-2024
- NDRA 11-15-2024
- Dividend Yield
- ARTL N/A
- NDRA N/A
- EPS Growth
- ARTL N/A
- NDRA N/A
- EPS
- ARTL N/A
- NDRA N/A
- Revenue
- ARTL N/A
- NDRA N/A
- Revenue This Year
- ARTL N/A
- NDRA N/A
- Revenue Next Year
- ARTL N/A
- NDRA N/A
- P/E Ratio
- ARTL N/A
- NDRA N/A
- Revenue Growth
- ARTL N/A
- NDRA N/A
- 52 Week Low
- ARTL $0.91
- NDRA $4.01
- 52 Week High
- ARTL $1.75
- NDRA $2,240.00
- Technical
- Relative Strength Index (RSI)
- ARTL 64.07
- NDRA 51.58
- Support Level
- ARTL $1.09
- NDRA $5.60
- Resistance Level
- ARTL $1.19
- NDRA $6.29
- Average True Range (ATR)
- ARTL 0.06
- NDRA 0.60
- MACD
- ARTL 0.01
- NDRA 0.02
- Stochastic Oscillator
- ARTL 100.00
- NDRA 27.29
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.